Skip to content
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP

Fennec Pharmaceuticals Inc. FENC

19 fiscal years on record · USD · FY2025 reported · SEC filings only
$44.6M
▼ 6.1% YoY
$-9.7M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 44.6M
Revenue, FY2025 · full 19-year series below
Revenue $M Net income $M
FY2025 · Revenue 44.6 · Net income -9.7
20M40M-10M-20M
2007201020132016201920222025
Compound annual growth
+207.5%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−22 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -14.1% · Net -21.8%
-5000%-10000%
200720162025
ROE
FY2021 · ROE -77.4%
-50%-100%-150%
200720162025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.

Return on equity has no reading this year — return on capital employed, just below, still does: -13%.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2013 · FCF -2.2
-2M-3M
200720162025

Total assetsUSD 70.6M
EquityUSD 35.5M
CashUSD 36.8M
Current ratio6.37×

Equity funds 50% of total assets.

The 19-year record

19 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
FENC, 19-year financial record
Metric 2025202420232022202120202019201820172016201520142013201220112010200920082007
Revenue $B0.00.00.00.0◌0.00.00.00.00.00.00.00.00.00.0◌◌◌◌
Operating income $B−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌◌
EBITDA $B◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Income tax $B0.00.0◌0.00.00.00.00.00.00.00.00.00.00.0◌◌◌◌◌
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.00.0−0.00.0−0.0−0.0−0.0−0.0
Free cash flow $B◌◌◌◌◌◌◌◌◌◌◌◌−0.0−0.0−0.0◌◌◌◌
EPS, diluted $−0.34−0.02−0.60−0.90−0.67−0.76−0.64−0.52−0.47−0.22−0.06−0.220.17−0.210.19−0.49◌◌◌
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————————————————
ROE %————−77.4−88.5−77.0−41.1−46.5−135.5−113.5—————−174.2−158.1−94.4
Shares out B0.030.030.030.030.030.030.020.020.020.010.010.010.030.030.000.02◌◌◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 69 reconciliationsAUDITED

Reconciled in 19 of the 19 fiscal years we could check. 15 checks were skipped: cost of revenue is not tagged before 2022. Six checks were skipped: the balance sheet is not tagged before 2010. Three checks were skipped: EPS is not tagged before 2010.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inoutside the United States — SEC code A1
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2007

Share this section

Download image